Turn Therapeutics Inc. (NASDAQ:TTRX) announced the appointment of Stephen M. Hahn, M.D., former FDA Commissioner, to oversee clinical and regulatory strategy for its investigational topical therapy GX-03.
Hahn served as the 24th FDA Commissioner from 2019 to 2021. He previously held executive roles at MD Anderson Cancer Center.
GX-03 is in Phase 2 trials for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026.
The company has a market cap of $121 million, with a consensus price target of $8 per share.
